{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:15Z","timestamp":1794047355491,"version":"4.8.0"},"reference-count":17,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2020.249649","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T17:35:14Z","timestamp":1587058514000},"page":"614-618","source":"Crossref","is-referenced-by-count":9,"title":["Myeloid\/lymphoid neoplasms with eosinophilia\/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition"],"prefix":"10.3324","volume":"106","author":[{"family":"JinJuan Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lianrong Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Umut Aypar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Howard J. Meyerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dory Londono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qi Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jeeyeon Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"James Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ryma Benayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Allison Sigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mariko Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ahmet Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maria E. Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mikhail Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yanming Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Michael J. Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wenbin Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"20786","doi-asserted-by":"crossref","unstructured":"Xie W, Wang SA, Hu S, Xu J, Medeiros LJ, Tang G. Myeloproliferative neoplasm with ABL1\/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. Cancer Gen. 2018; 228-229:41-46.","DOI":"10.1016\/j.cancergen.2018.08.002"},{"key":"20787","doi-asserted-by":"crossref","unstructured":"Zaliova M, Moorman AV, Cazzaniga G. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016; 101(9):1082-1093.","DOI":"10.3324\/haematol.2016.144345"},{"key":"20788","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Vieira SA, Connors S. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood. 2002; 99(9):3465-3467.","DOI":"10.1182\/blood.V99.9.3465"},{"key":"20789","doi-asserted-by":"crossref","unstructured":"Kelly JC, Shahbazi N, Scheerle J. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1\/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Gen Cytogenet. 2009; 192(1):36-39.","DOI":"10.1016\/j.cancergencyto.2009.02.012"},{"key":"20790","doi-asserted-by":"crossref","unstructured":"Barbouti A, Ahlgren T, Johansson B. Clinical and genetic studies of ETV6\/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol. 2003; 122(1):85-93.","DOI":"10.1046\/j.1365-2141.2003.04391.x"},{"key":"20791","doi-asserted-by":"crossref","unstructured":"Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res. 2016; 4(1):16.","DOI":"10.1186\/s40364-016-0070-7"},{"key":"20792","doi-asserted-by":"crossref","unstructured":"Kakadia PM, Schmidmaier R, Volkl A. An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to imatinib followed by rapid transformation into ALL. Leuk Res Rep. 2016; 6:50-54.","DOI":"10.1016\/j.lrr.2016.09.002"},{"key":"20793","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Yakushijin K, Nakamachi Y. Extramedullary Tlymphoid blast crisis of an ETV6\/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2). Ann Hematol. 2014; 93(8):1435-1438.","DOI":"10.1007\/s00277-013-1975-y"},{"key":"20794","unstructured":"La Starza R, Trubia M, Testoni N. Clonal eosinophils are a morphologic hallmark of ETV6\/ABL1 positive acute myeloid leukemia. Haematologica. 2002; 87(8):789-794."},{"key":"20795","doi-asserted-by":"crossref","unstructured":"Park J, Kim M, Lim J. Variant of ETV6\/ABL1 gene is associated with leukemia phenotype. Acta Haematol. 2013; 129(2):78-82.","DOI":"10.1159\/000342490"},{"key":"20796","doi-asserted-by":"crossref","unstructured":"Perna F, Abdel-Wahab O, Levine RL, Jhanwar SC, Imada K, Nimer SD. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica. 2011; 96(2):342-343.","DOI":"10.3324\/haematol.2010.036673"},{"key":"20797","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"20798","doi-asserted-by":"crossref","unstructured":"Sakai H, Hosono N, Nakazawa H. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. Leukemia. 2018; 32(3):839-843.","DOI":"10.1038\/leu.2017.319"},{"key":"20799","doi-asserted-by":"crossref","unstructured":"Haferlach C, Bacher U, Kohlmann A. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica. 2011; 96(6):829-836.","DOI":"10.3324\/haematol.2010.035584"},{"key":"20800","doi-asserted-by":"crossref","unstructured":"Haferlach C, Bacher U, Schnittger S. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012; 51(4):328-337.","DOI":"10.1002\/gcc.21918"},{"key":"20801","doi-asserted-by":"crossref","unstructured":"Choi SI, Jang MA, Jeong WJ. A case of chronic myeloid leukemia with rare variant ETV6\/ABL1 rearrangement. Ann Lab Med. 2017; 37(1):77-80.","DOI":"10.3343\/alm.2017.37.1.77"},{"key":"20802","doi-asserted-by":"crossref","unstructured":"Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol. 2004; 24(11):4685-4695.","DOI":"10.1128\/MCB.24.11.4685-4695.2004"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9719\/70778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9719\/70779","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9719\/70778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:47Z","timestamp":1794045407000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.249649","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}